Physician profile
Molly E Griffin
NPI 1225104649
$973.86
in general payments reported to CMS, 2019-2025
15 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $167 · 2021: $30.38 · 2022: $98.24 · 2023: $224 · 2024: $120 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $516.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $238.87 | 2020-2025 | |
| Galderma Laboratories, L.P. | $156.61 | 2019-2025 | Aklief, Epsolay, Twyneo |
| Pfizer INC. | $117.19 | 2019-2022 | |
| Incyte Corporation | $83.74 | 2023-2025 | Opzelura |
| Journey Medical Corporation | $80.74 | 2020-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.13 | 2020-2024 | Cabtreo |
| Sun Pharmaceutical Industries INC. | $43.96 | 2022-2025 | |
| Vyne Pharmaceuticals INC. | $34.14 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $32.39 | 2023 | Dupixent |
| Organon LLC | $29.89 | 2025 | Vtama |
| Allergan, INC. | $28.11 | 2022 | |
| Janssen Biotech, INC. | $22.07 | 2022 | |
| Mission Pharmacal Company | $19.20 | 2019 | |
| Mayne Pharma Commercial LLC | $19.03 | 2024 | |
| Aclaris Therapeutics, INC. | $17.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.